GSK wins US approval for Jideytro in previously treated ROS1-positive lung cancer
The FDA cleared the ROS1 inhibitor ahead of schedule, marking GSK's first lung cancer approval and its first product from the Nuvalent acquisition.
SEC filing
Latest
Wednesday, July 22
LB Pharmaceuticals moves up NOVA-2 schizophrenia trial readout to first half of 2027
The company cited faster-than-expected enrollment as the reason for pulling forward its Phase 3 timeline for LB-102.
SEC filing
Novo Nordisk registers Phase 3 obesity trial for zenagamtide; MTC safety study enrolling
Tuesday, July 21
Apollomics discloses full compensation and bio details for new director Yen
A follow-up SEC filing confirms Hung-Hsien Yen's board appointment and lays out his pay package and background.
SEC filing
VYNE approves 1-for-50 reverse split, sets special dividend ahead of Yarrow merger
VYNE Therapeutics will pay a $17.3 million cash dividend and complete a reverse stock split before its merger with Yarrow Bioscience closes around July 24, 2026.
SEC filing
Innate Pharma completes enrollment in Phase 1 study of Nectin-4 ADC IPH4502
The company enrolled 76 patients in the dose-escalation portion of the trial, with preliminary data expected by year-end 2026.
SEC filing
Gemelli registers interventional EV trial mapping vascular complications in systemic sclerosis
Krystal Biotech registers early-phase trial of KB111 gene therapy for Hailey-Hailey Disease
Context Therapeutics posts results for terminated elacestrant-onapristone breast cancer trial
Abeona Therapeutics, Inc updates registry record NCT07717736: not yet recruiting
Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 for MDD
The trial, testing HLP003 as an adjunctive MDD treatment, finished enrollment ahead of schedule with topline data still expected in Q4 2026.
SEC filing
PDS Biotechnology registers shares tied to YA II PN note and warrant
The prospectus covers resale of up to 13,315,823 shares issuable to YA II PN, LTD. from a $6 million promissory note and a warrant tied to an April 2026 purchase agreement.
SEC filing
Jupiter Neurosciences signs U.S. license deal with PharmAla for ALA-002
The definitive agreement replaces a May non-binding term sheet and sets upfront, milestone, and royalty payments tied to ALA-002 development in the U.S.
SEC filing
Novartis posts ASSIST Phase 2 results; two pediatric studies listed
Alterity Therapeutics CEO to attend BTIG Biotechnology Conference 2026
David Stamler will hold one-on-one investor meetings during the virtual conference set for July 28-29, 2026.
SEC filing
Tonix Pharmaceuticals CMO Gregory Sullivan to retire in August 2026
The company disclosed the retirement in an 8-K filing dated July 21, 2026, with an effective date the following month.
SEC filing
Sol-Gel posts terminated Phase 2 patidegib gel trial results; 2 of 47 had serious adverse events
Phio Pharmaceuticals adds dermatologist R. Todd Plott to board
Phio expanded its board to six members effective July 20, 2026, naming Plott a director and a member of its Governance Committee.
SEC filing
Polaryx Therapeutics' chief medical officer resigns effective immediately
Lisa Bollinger's departure was disclosed in a July 21, 2026 filing, with the company saying it does not expect the move to disrupt existing plans.
SEC filing
Axsome registers two Phase 3 solriamfetol trials in pediatric and adolescent ADHD
PolyPid partners with Azurity to commercialize D-PLEX100 in U.S. and Canada
PolyPid could receive over $320 million in payments as Azurity takes on U.S. and Canadian commercial rights for the surgical infection candidate, with launch targeted for early 2027.
SEC filing
Janssen registers Phase 3 esketamine nasal spray trial for treatment-resistant depression
Monday, July 20
Organigram updates on Sanity Group's initial performance and Canadian market share
Organigram said Sanity Group has held about 10% German market share since the April 2026 close, while Canadian recreational share sat at 11.1% at end of June.
SEC filing
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinoma
Nine trial sites are activated and treating patients in the randomized study, with a data update expected in 2027 and completion in 2028.
SEC filing
Armata Pharmaceuticals names David House chief financial officer
The company elevated House from senior finance officer to CFO effective July 17, 2026, under a new employment agreement filed with the SEC.
SEC filing
REGENXBIO closes $100 million offering after underwriters exercise full overallotment
The gene therapy company finalized its stock and warrant sale on July 20, 2026, with net proceeds expected near $107.8 million after the underwriters' option was exercised in full.
SEC filing (3)
Damora Therapeutics completes move from Delaware to Cayman Islands
The redomestication took effect July 16, 2026, with shares set to trade under a new CUSIP starting July 20, but the company said its operations remain unchanged.
SEC filing
Xencor's Phase 1 trial of XmAb412 in healthy volunteers is recruiting
Sunshine Biopharma files $4 million at-the-market stock offering with Aegis Capital
The prospectus supplement, dated July 20, 2026, lets Sunshine Biopharma sell shares through Aegis as sales agent for general corporate purposes.
SEC filing
Actuate registers Phase 1/2 trial of oral elraglusib in advanced solid tumors
Optimi Health CEO Dane Stevens buys 18,700 shares in mid-July trades
The purchases, made indirectly through a controlled company, lifted Stevens' beneficial holdings to 452,547 shares.
SEC filing
Mesoblast CEO Itescu exercises options, boosting stake to over 80.8 million shares
Silviu Itescu paid A$2,733,734 to exercise options, according to a company filing dated July 21, 2026.
SEC filing
Elutia to sell SimpliDerm business to Cellution Biologics for up to $11 million
The divestiture is meant to fund Elutia's push toward its NXT-41x biomatrix, which the company expects to clear regulatory review and launch commercially in 2027.
SEC filing
Lilly completes Phase 3 ATTAIN-J trial of oral orforglipron in Japanese obesity patients
Oncolytics wins FDA Fast Track for pelareorep in second-line anal cancer
The designation applies to pelareorep paired with a checkpoint inhibitor in advanced anal cancer patients whose disease progressed after prior treatment.
SEC filing
Dana-Farber registers Phase 2 zanzalintinib trial for rare adrenal tumors, Exelixis collaborating
BeOne Medicines-linked "High Five" Phase 3 NSCLC trial registered, not yet recruiting
Armata reports FDA submissions complete ahead of AP-SA02 Phase 3
The company said it has submitted all requested clinical, CMC, and regulatory responses to the FDA following its End-of-Phase 2 meeting for AP-SA02.
SEC filing
Kalaris Therapeutics names Liisa Bayko as chief financial officer
The Nasdaq company also disclosed the resignation of its chief accounting officer and named an interim replacement, per a filing dated July 20, 2026.
SEC filing
Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics study
Sunshine Biopharma sets up $4 million at-the-market stock sale facility with Aegis Capital
The company can sell up to $4,000,000 of common stock over time through Aegis Capital under a new sales agreement dated July 20, 2026.
SEC filing